Table 4.
Association between TIM-3 and clinical parameters in solid cancers.
| Categories | Number of studies | Model | OR (95% CI) | Heterogeneity | P-value | |
|---|---|---|---|---|---|---|
| I2 | PH value | |||||
| Gender (Female vs. Male) | 13 | Fixed | 1.01 (0.83–1.24) | 0.0% | 0.966 | 0.893 |
| Age (≥60 vs. <60) | 12 | Fixed | 1.19 (0.99–1.43) | 0.0% | 0.601 | 0.064 |
| T stage (T3~T4 vs. T1~T2) | 8 | Random | 1.07 (0.59–1.95) | 79.2% | <0.001 | 0.825 |
| Lymph node metastasis (N+ vs. N–) | 8 | Random | 1.59 (1.10–2.29) | 56.1% | 0.025 | 0.013 |
| Grade (Grade2–3 vs. Grade1) | 9 | Fixed | 1.68 (1.21–2.34) | 0.0% | 0.700 | 0.002 |
| TNM Stage (III–IV vs. I–II) | 12 | Random | 1.41 (0.91–2.17) | 69.3% | <0.001 | 0.122 |
| Smoking (Yes vs. no) | 6 | Fixed | 1.13 (0.85–1.50) | 39.4% | 0.129 | 0.394 |
| Distant metastasis (Yes vs. no) | 2 | Fixed | 1.58 (0.58–4.33) | 42.3% | 0.177 | 0.371 |
| Vascular invasion (Yes vs. no) | 4 | Random | 1.22 (0.71–2.12) | 57.6% | 0.070 | 0.471 |
| PD−1(High vs. low) | 3 | Fixed | 3.26 (2.20–4.82) | 40.8% | 0.185 | <0.001 |
N-, lymph node negative; N+, lymph node positive; PD-1; programmed cell death protein-1.